At the core of our CDMO-heart is a deep-rooted commitment to the life sciences community. 💗 That's why we at NorthX Biologics are proud to regularly engage with students, sharing our expertise and insights while learning from the next generation of innovators. These interactions inspire us to continue building bridges between industry and academia, fostering an environment where scientific progress and innovation can thrive. We're excited to keep pushing the boundaries of what's possible, together. The future of life sciences has never looked brighter. 🌞 Uppsala University | Umeå University Christoffer Ahlström | Johan Persäter | Luisa Lundin #BeyondCDMO

🤩 Excited for the upcoming Advances in Cell-Based Screening for Drug Discovery conference in Gothenburg this week! Can't wait to connect with fellow attendees. 🤝 If you're going to be there and would like to catch up, feel free to reach out. You can also locate me by my poster (#51) with the title "DEVELOPMENT OF A NEW AFFINITY RANKING METHOD USING LIGANDTRACER TECHNOLOGY IN REAL-TIME ON LIVE CELLS". 📜 #LigandTracer #DiscoverMolecularInteractions  #realtimebindinginteractions #drugdesign 

Molecules of the Month - June Edition In this edition of Molecules of the Month, LCC are excited to announce our updated and improved Fragment Library. Find out how LCC's 3D-rich, stereo-defined, novel Fragment Library can accelerate your drug discovery programmes. 👇 #FBDD #DrugDiscovery

Celebrating Excellence in Science and Innovation   NanoVation Therapeutics is proud to share an incredible milestone for its leadership team. Clarivate revealed the Highly Cited Researchers 2024 List (read more here: https://sl8.in/pQD2klVe), recognizing the world’s most influential scientists—and we are thrilled to see our own leaders included.   Dominik Witzigmann, PhD, CEO, Pieter Cullis, Board Chair, and Jayesh Kulkarni, CSO  have been recognized for their exceptional contributions to science and their profound impact on the global research community.    💡This accomplishment not only highlights their individual expertise but also reflects the scientific strength of NanoVation Therapeutics’ mission to develop innovative technologies that overcome the barriers to nucleic acid delivery, addressing some of the most pressing healthcare challenges.   NTx continues to push the boundaries of innovation, and this is only the beginning. Follow this page for more updates as the company builds on its mission to shape the future of healthcare.   #NanoVationTherapeutics #Innovation #Biotech #GeneticMedicine #RNA #LNP #NucleicAcids

Looking forward to talking about our efforts on cancer drug discovery using single-cell omics and AI

Ready to Revolutionize Drug Discovery? Our groundbreaking Bioluminescent Thermal Shift Assay (BiTSA) is making this a reality! Imagine detecting drug-target interactions with precision and speed. BiTSA combines high sensitivity with high-throughput capabilities, providing the crucial data you need to accelerate your drug discovery process. Want to see BiTSA in action? Check out our latest case study and discover how we're transforming drug development. Click here to learn more: https://lnkd.in/g3RQ_aAu

Biology Building Block - p38 BiTSA assay to measure target engagement in cells. Target: p38α/MAPK14 Assay type: Protein stabilization assay Purpose: Protein and molecule binding in cells Fast assay development: 5-7 days Throughput: 384-well plate Turnaround time: 2 days Automation: Available #BiTSA assay #Assaydevelopment #Drugscreening #HiBiT based techonology

Have you caught up with all the news from Domainex in its latest newsletter? Content includes a cryo-EM case study, details of its drug discovery webinar series, updates on advances made in high-throughput experimentation and direct-to-biology plus publications and events. Find it here - https://ow.ly/Zz9350UlZoj

Check out the new features and resources on Condensates.com!

If you're putting together a Weight of Evidence dossier to submit to the regulators - in order to support your position that a 2-year rat carc study won't provide any value to your NDA submission - taking advantage of your existing SEND data can play a big role. This presentation drew a full house at ACT. Take a look and let me know if you have any questions. #ACT #S1B #SEND